Vitafusion Launches NMN Gummies Following FDA's Previous Reversal on the Ingredient

Piping Rock Health Products has launched Vital NMN Gummies under its Vitafusion brand, delivering 300 mg of nicotinamide mononucleotide (NMN), a precursor to NAD+, in a Tropical Glow-flavored gummy positioned around healthy aging and cellular health.¹

The launch is built around a TikTok-first marketing campaign under the tagline "Aging? Love It.," aimed at repositioning the brand for a younger audience seeking wellness products through social platforms rather than traditional retail discovery.

For manufacturers, the timing is notable: NMN spent roughly 2 years in a regulatory gray area after the FDA determined the ingredient had been excluded from the dietary supplement definition in 2022, a position the agency began reversing in the second half of 2025.

"With 'Aging? Love It.,' we're flipping the conversation around healthy aging," said Tina Dobush, Vitafusion’s vice president of marketing and communications. "It's not about turning back the clock or believing the best years are behind you. It's about embracing where you are, supporting where you're going, and making wellness something you can genuinely enjoy along the way."

What Is Vital NMN, and What Dose Does the New Product Deliver?

The gummy delivers 300 mg of what the company calls Vital NMN Bioactive Nucleotide per serving, positioned as supporting NAD+ levels, cellular repair, energy, and metabolism. NAD+ is a coenzyme involved in cellular energy metabolism that declines with age, which is the basic biological rationale marketed NMN products rely on.

Why Did NMN's Regulatory Status Matter for This Launch?

NMN's path to market has been unsettled in recent years. In October 2022, the FDA determined that NMN was excluded from the legal definition of a dietary supplement because a company had first studied it as a drug candidate, a disqualifying sequence under the Food, Drug, and Cosmetic Act's drug preclusion clause.

After reconsidering citizen petitions challenging that position, the FDA reversed course, concluding that NMN is not excluded from the dietary supplement definition, and by December 2025 was issuing letters acknowledging new dietary ingredient notifications for NMN submitted by individual manufacturers.²

That reversal removed a significant compliance overhang for any brand considering an NMN launch, though the FDA was explicit that accepting such a notification is a procedural step, not a safety determination, and that it retains authority to act against any NMN product found to be unsafe, adulterated, or misbranded.²

What Does the Clinical Evidence on NMN Actually Show?

A 2026 systematic review and meta-analysis in Nutrients pooled data from 15 randomized controlled trials, with a safety-focused subset of 10 trials covering 383 participants who received NMN doses ranging from 250 to 2,000 mg daily for up to 24 weeks.³ The analysis found NMN did not increase overall or serious adverse events and did not significantly affect liver enzymes, indicating favorable short-term tolerability at doses that include the amount used in Vitafusion's new product.

However, the same review found no significant effects on body weight, fasting glucose, or lipid profiles, with only a modest, non-significant trend toward improved insulin resistance markers, findings the authors described as requiring confirmation in larger, longer trials rather than as established metabolic benefits.³

References

1. Vitafusion says "Aging? Love it." with launch of Vital NMN gummies. PR Newswire. September 16, 2026. Accessed September 21, 2026. https://www.prnewswire.com/news-releases/vitafusion-says-aging-love-it-with-launch-of-vital-nmn-gummies-302880666.html

2. US Food and Drug Administration. Letter re: NMN new dietary ingredient notification, response to citizen petition on drug preclusion. December 2, 2025. Accessed September 21, 2026. https://downloads.regulations.gov/FDA-2022-S-0023-0069/attachment_1.pdf

3. Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients. 2026;18(14):2251. doi:10.3390/nu18142251